Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
First Claim
Patent Images
1. A method of ameliorating or treating at least one symptom of a neurodegenerative diseases in a subject comprising:
- administering to a subject a clear aqueous solution comprising;
(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and a bile acid conjugated with an amine by an amide linkage;
(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product or an aqueous soluble non-starch polysaccharide;
(c) water, wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values.
0 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure is related to clear aqueous solutions of one or more bile acids and either an aqueous soluble starch conversion product or a non-starch polysaccharide. Solutions of the disclosure may be administered to a subject in conjunction with a pharmaceutical compound having a therapeutic effect in subjects with a neurodegenerative disease and/or a motor neuron disease. In some embodiments, the disease is amyotrophic lateral sclerosis.
121 Citations
68 Claims
-
1. A method of ameliorating or treating at least one symptom of a neurodegenerative diseases in a subject comprising:
-
administering to a subject a clear aqueous solution comprising;
(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and a bile acid conjugated with an amine by an amide linkage;
(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product or an aqueous soluble non-starch polysaccharide;
(c) water, wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A method of ameliorating or treating at least one symptom of a motor neuron disease in a subject comprising:
-
administering to a subject a clear aqueous solution comprising;
(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and a bile acid conjugated with an amine by an amide linkage;
(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product or an aqueous soluble non-starch polysaccharide;
(c) water, wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
-
29. A method for ameliorating or treating at least one symptom of a neurodegenerative disease or at least one symptom of a motor neuron disease in a subject comprising:
-
administering a pharmaceutical compound to the subject; and
administering to the subject a clear aqueous solution comprising;
(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and a bile acid conjugated with an amine by an amide linkage;
(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product or an aqueous soluble non-starch polysaccharide;
(c) water, wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values;
- View Dependent Claims (30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)
-
-
58. A clear aqueous solution comprising:
-
(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and a bile acid conjugated with an amine by an amide linkage;
(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product or an aqueous soluble non-starch polysaccharide;
(c) a pharmaceutically effective amount of a pharmaceutical compound that decreases motor neuron death; and
(d) water, wherein the first material, the carbohydrate, and the riluzole all remain in solution for all pH values of the solution within a selected range of pH values. - View Dependent Claims (59, 60, 61, 62, 63, 64, 65, 66, 67, 68)
-
Specification